

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**丽珠医药**  
**LIVZON**

**麗珠醫藥集團股份有限公司**

**LIVZON PHARMACEUTICAL GROUP INC.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1513)**

## **COMPLETION OF REGISTRATION OF THE RESERVED GRANT OF THE 2022 SHARE OPTIONS INCENTIVE SCHEME**

References are made to the circular of the Company dated 27 September 2022 (the “**Circular**”) and the announcement of the Company dated 30 October 2023 in relation to the proposed adoption of the Incentive Scheme and the Reserved Grant respectively. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meaning as those defined in the Circular.

On 30 October 2023, the Company granted 2,000,000 Share Options to 243 Incentive Participants pursuant to the Reserve Grant under the Incentive Scheme.

On 28 November 2023, the Reserved Grant has completed registration. The abbreviation of the Share Options: Livzon JLC4. The code of the Share Options is 037409.

By order of the Board

**麗珠醫藥集團股份有限公司**

**Livzon Pharmaceutical Group Inc. \***

**Yang Liang**

*Company Secretary*

Zhuhai, China

29 November 2023

*As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.*

*\* For identification purpose only*